Scientific Reports · 2014 · 39 citations · 20 references
MedicineImmunologyOncologyBiomedical ImagingImmunotherapyMolecular ImagingAntitumor T Cell ResponsesCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyTargeted Imaging AgentsTheranostic NanoparticlesTumor-associated AntigensCell Dose DeterminationCell Therapy Dose OptimizationMolecular Contrast AgentsParamagnetic Contrast AgentsT Cell-based ImmunotherapyTumor-associated Antigen RecognitionTumor-associated Antigen TargetingWhole-body Pet Imaging
Genetically-modified T cells expressing chimeric antigen receptors (CAR) exert anti-tumor effect by identifying tumor-associated antigen (TAA), independent of major histocompatibility complex. For maximal efficacy and safety of adoptively transferred cells, imaging their biodistribution is critical. This will determine if cells home to the tumor and assist in moderating cell dose. Here, T cells are modified to express CAR. An efficient, non-toxic process with potential for cGMP compliance is developed for loading high cell number with multi-modal (PET-MRI) contrast agents (Super Paramagnetic Iron Oxide Nanoparticles - Copper-64; SPION-(64)Cu). This can now be potentially used for (64)Cu-based whole-body PET to detect T cell accumulation region with high-sensitivity, followed by SPION-based MRI of these regions for high-resolution anatomically correlated images of T cells. CD19-specific-CAR(+)SPION(pos) T cells effectively target in vitro CD19(+) lymphoma.
20
Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles
Ayush Verma, Oktay Uzun, Yuhua Hu et al. · Nature Materials · 2008 · 1.3K citations · Full text